 This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with early rheumatoid arthritis. Patients will be randomized to receive either tocilizumab 8mgkg iv every 4 weeks plus weekly methotrexate po in ascending doses, or tocilizumab 8mgkg iv every 4 weeks plus placebo, or methotrexate plus placebo. Anticipated time on study treatment is 2 years, and target sample size is 300. 